Table of Contents
Advances in Nephrology
Volume 2014 (2014), Article ID 727135, 7 pages
http://dx.doi.org/10.1155/2014/727135
Review Article

Fragility Fractures in Chronic Kidney Disease: Assessment and Pharmacologic Management

1Department of Internal Medicine, Eastern Health, Albert Street, Melbourne, VIC 3156, Australia
2Department of Medicine, North West Academic Centre, University of Melbourne, St. Albans, Melbourne, VIC 3021, Australia
3Division of Internal Medicine, Western Health, Gordon Street, Melbourne, VIC 3011, Australia
4University of Melbourne, Melbourne, VIC 3010, Australia

Received 28 May 2014; Accepted 25 August 2014; Published 16 September 2014

Academic Editor: Francois Madore

Copyright © 2014 Mahesan Anpalahan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Alem, D. J. Sherrard, D. L. Gillen et al., “Increased risk of hip fracture among patients with end-stage renal disease,” Kidney International, vol. 58, no. 1, pp. 396–399, 2000. View at Google Scholar
  2. T. L. Nickolas, D. J. McMahon, and E. Shane, “Relationship between moderate to severe kidney disease and hip fracture in the United States,” Journal of the American Society of Nephrology, vol. 17, no. 11, pp. 3223–3232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Levin, G. L. Bakris, M. Molitch et al., “Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease,” Kidney International, vol. 71, no. 1, pp. 31–38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Kanis and J. A. Kanis, “Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report,” Osteoporosis International, vol. 4, no. 6, pp. 368–381, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. T. L. Nickolas, E. Stein, A. Cohen et al., “Bone mass and microarchitecture in CKD patients with fracture,” Journal of the American Society of Nephrology, vol. 21, no. 8, pp. 1371–1380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. A. Jamal, J. A. Hayden, and J. Beyene, “Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis,” The American Journal of Kidney Diseases, vol. 49, no. 5, pp. 674–681, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. “KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),” Kidney International. Supplement, vol. 113, pp. S1–S130, 2009. View at Publisher · View at Google Scholar
  8. V. M. Brandenburg and J. Floege, “Adynamic bone disease—bone and beyond,” NDT Plus, vol. 1, no. 3, pp. 135–147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Ambrus, A. Marton, Z. K. Nemeth, and I. Mucsi, “Bone mineral density in patients on maintenance dialysis,” International Urology and Nephrology, vol. 42, no. 3, pp. 723–739, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Gerakis, D. Hadjidakis, E. Kokkinakis, T. Apostolou, S. Raptis, and A. Billis, “Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis,” Journal of Nephrology, vol. 13, no. 6, pp. 437–443, 2000. View at Google Scholar · View at Scopus
  11. J. Bacchetta, S. Boutroy, N. Vilayphiou et al., “Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease,” Journal of Bone and Mineral Research, vol. 25, no. 4, pp. 849–857, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. F. W. Wehrli, M. B. Leonard, P. K. Saha, and B. R. Gomberg, “Quantitative high-resolution magnetic resonance imaging reveals structural implications of renal osteodystrophy on trabecular and cortical bone,” Journal of Magnetic Resonance Imaging, vol. 20, no. 1, pp. 83–89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. T. L. Nickolas, S. Cremers, A. Zhang et al., “Discriminants of prevalent fractures in chronic kidney disease,” Journal of the American Society of Nephrology, vol. 22, no. 8, pp. 1560–1572, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Urena and M.-C. de Vernejoul, “Circulating biochemical markers of bone remodeling in uremic patients,” Kidney International, vol. 55, no. 6, pp. 2141–2156, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Lehmann, U. Ott, D. Kämmerer, J. Schütze, and G. Wolf, “Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3–5,” Clinical Nephrology, vol. 70, no. 4, pp. 296–305, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. R. J. Bervoets, G. B. Spasovski, G. J. Behets et al., “Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients,” The American Journal of Kidney Diseases, vol. 41, no. 5, pp. 997–1007, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Swaminathan, “Biochemical markers of bone turnover,” Clinica Chimica Acta, vol. 313, no. 1-2, pp. 95–105, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. J. H. Krege, N. E. Lane, J. M. Harris et al., “PINP as a biological response marker during teriparatide treatment for osteoporosis,” Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 25, no. 9, pp. 2159–2171, 2014. View at Google Scholar
  19. Q. Qi, M.-C. Monier-Faugere, Z. Geng, and H. H. Malluche, “Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis,” The American Journal of Kidney Diseases, vol. 26, no. 4, pp. 622–631, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. M. M. Couttenye, P. C. D'Haese, V. O. van Hoof et al., “Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 11, no. 6, pp. 1065–1072, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Gal-Moscovici and M. M. Popovtzer, “New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels,” Clinical Nephrology, vol. 63, no. 4, pp. 284–289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. J. A. Kanis, O. Johnell, A. Oden, H. Johansson, and E. McCloskey, “FRAX and the assessment of fracture probability in men and women from the UK,” Osteoporosis International, vol. 19, no. 4, pp. 385–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. N. D. Nguyen, S. A. Frost, J. R. Center, J. A. Eisman, and T. V. Nguyen, “Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks,” Osteoporosis International, vol. 19, no. 10, pp. 1431–1444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. K. E. Ensrud, L.-Y. Lui, B. C. Taylor et al., “Renal function and risk of hip and vertebral fractures in older women,” Archives of Internal Medicine, vol. 167, no. 2, pp. 133–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. T. E. Larsson, “The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe?” Nephrology Dialysis Transplantation, vol. 25, no. 5, pp. 1376–1381, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Isakova, P. Wahl, G. S. Vargas et al., “Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease,” Kidney International, vol. 79, no. 12, pp. 1370–1378, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Shalhoub, E. M. Shatzen, S. C. Ward et al., “FGF23 neutralization improves chronic kidney disease—associated hyperparathyroidism yet increases mortality,” Journal of Clinical Investigation, vol. 122, no. 7, pp. 2543–2553, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Pelletier, L. Dubourg, M.-C. Carlier, A. Hadj-Aissa, and D. Fouque, “The relation between renal function and serum sclerostin in adult patients with CKD,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 5, pp. 819–823, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Tonelli, N. Wiebe, B. Culleton et al., “Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients,” Nephrology Dialysis Transplantation, vol. 22, no. 10, pp. 2856–2866, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. A. J. Hutchison, B. Maes, J. Vanwalleghem et al., “Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate,” Nephron: Clinical Practice, vol. 100, no. 1, pp. c8–c19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. J. B. Cannata-Andia, J. T. Harrington, M. Martinez-Maldonado et al., “Hypokinetic azotemic osteodystrophy,” Kidney International, vol. 54, no. 3, pp. 1000–1016, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. A. C. Alfrey, A. Hegg, and P. Craswell, “Metabolism and toxicity of aluminum in renal failure,” The American Journal of Clinical Nutrition, vol. 33, no. 7, pp. 1509–1516, 1980. View at Google Scholar · View at Scopus
  33. R. Rizzoli, S. Boonen, M. L. Brandi et al., “Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO),” Current Medical Research and Opinion, vol. 29, no. 4, pp. 305–313, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. S. L. West, V. J. Swan, and S. A. Jamal, “Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population,” Clinical Journal of the American Society of Nephrology, vol. 5, supplement 1, pp. S41–S47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Bolland, P. A. Barber, R. N. Doughty et al., “Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial,” BMJ, vol. 336, no. 7638, pp. 262–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. “K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease,” American Journal of Kidney Diseases, vol. 42, no. 4, supplement 3, pp. S1–S201, 2003.
  37. A. Torres, V. Lorenzo, D. Hernandez et al., “Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH,” Kidney International, vol. 47, no. 5, pp. 1434–1442, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Cunningham, M. Danese, K. Olson, P. Klassen, and G. M. Chertow, “Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism,” Kidney International, vol. 68, no. 4, pp. 1793–1800, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. J. H. Lin, “Bisphosphonates: a review of their pharmacokinetic properties,” Bone, vol. 18, no. 2, pp. 75–85, 1996. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Conte and V. Guarneri, “Safety of intravenous and oral bisphosphonates and compliance with dosing regimens,” The Oncologist, vol. 9, supplement 4, pp. 28–37, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. D. J. Sherrard, G. Hercz, Y. Pei et al., “The spectrum of bone disease in end-stage renal failure—an evolving disorder,” Kidney International, vol. 43, no. 2, pp. 436–442, 1993. View at Publisher · View at Google Scholar · View at Scopus
  42. U. A. Liberman, S. R. Weiss, J. Bröll et al., “Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis,” New England Journal of Medicine, vol. 333, no. 22, pp. 1437–1443, 1995. View at Publisher · View at Google Scholar · View at Scopus
  43. D. M. Black, S. R. Cummings, D. B. Karpf et al., “Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures,” The Lancet, vol. 348, no. 9041, pp. 1535–1541, 1996. View at Publisher · View at Google Scholar · View at Scopus
  44. P. D. Miller, C. Roux, S. Boonen, I. P. Barton, L. E. Dunlap, and D. E. Burgio, “Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials,” Journal of Bone and Mineral Research, vol. 20, no. 12, pp. 2105–2115, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. S. A. Jamal, D. C. Bauer, K. E. Ensrud et al., “Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial,” Journal of Bone and Mineral Research, vol. 22, no. 4, pp. 503–508, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. D. M. Black, P. D. Delmas, R. Eastell et al., “Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis,” The New England Journal of Medicine, vol. 356, no. 18, pp. 1809–1822, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Boonen, D. E. Sellmeyer, K. Lippuner et al., “Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women,” Kidney International, vol. 74, no. 5, pp. 641–648, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. P. D. Miller, P. Ward, T. Pfister, C. Leigh, and J.-J. Body, “Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review,” Clinical and Experimental Rheumatology, vol. 26, no. 6, pp. 1125–1133, 2008. View at Google Scholar · View at Scopus
  49. P. D. Miller, “The kidney and bisphosphonates,” Bone, vol. 49, no. 1, pp. 77–81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. P. D. Miller, S. Ragi-Eis, C. Mautalen, F. Ramirez, and I. Jonkanski, “Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease: the DIVINE study,” Bone, vol. 49, no. 6, pp. 1317–1322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Ishani, T. Blackwell, S. A. Jamal, S. R. Cummings, and K. E. Ensrud, “The effect of raloxifene treatment in postmenopausal women with CKD,” Journal of the American Society of Nephrology, vol. 19, no. 7, pp. 1430–1438, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. P. D. Miller, E. N. Schwartz, P. Chen, D. A. Misurski, and J. H. Krege, “Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment,” Osteoporosis International, vol. 18, no. 1, pp. 59–68, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Cejka, K. Kodras, T. Bader, and M. Haas, “Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study,” Kidney and Blood Pressure Research, vol. 33, no. 3, pp. 221–226, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. G. A. Block, H. G. Bone, L. Fang, E. Lee, and D. Padhi, “A single-dose study of denosumab in patients with various degrees of renal impairment,” Journal of Bone and Mineral Research, vol. 27, no. 7, pp. 1471–1479, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. S. A. Jamal, Ö. Ljunggren, C. Stehman-Breen et al., “Effects of denosumab on fracture and bone mineral density by level of kidney function,” Journal of Bone and Mineral Research, vol. 26, no. 8, pp. 1829–1835, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. S. R. Cummings, J. S. Martin, M. R. McClung et al., “Denosumab for prevention of fractures in postmenopausal women with osteoporosis,” New England Journal of Medicine, vol. 361, no. 8, pp. 756–765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. B. B. Mccormick, J. Davis, and K. D. Burns, “Severe hypocalcemia following denosumab injection in a hemodialysis patient,” The American Journal of Kidney Diseases, vol. 60, no. 4, pp. 626–628, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. Novartis, “Salcatonin prescribing information,” http://www.novartis.com.au/pi_pdf/mia.pdf.
  59. Servier, Protos Prescribing Information, 2013, http://www.servier.co.uk/healthcare-professionals/protelos/references.asp.
  60. P. D. Miller, “Treatment of osteoporosis in chronic kidney disease and end-stage renal disease,” Curr Osteoporos Rep, vol. 3, no. 1, pp. 5–12, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. S. A. Jamal, C. J. Hamilton, R. Eastell, and S. R. Cummings, “Effect of nitroglycerin ointment on bone density and strength in postmenopausal women a randomized trial,” The Journal of the American Medical Association, vol. 305, no. 8, pp. 800–807, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. M. R. McClung, A. Grauer, and S. Boonen, “Romosozumab in women with low bone mineral density,” The New England Journal of Medicine, vol. 370, no. 5, pp. 412–420, 2014. View at Google Scholar